Update on combinations of DAAs with and without pegylated-interferon and ribavirin: triple and quadruple therapy more than doubles SVR.

Douglas T Dieterich, Valérie Martel-Laferrière

Journal: Clinics in liver disease 2013;17(1):93-103

PMID: 23177285

Full Text on Elsevier Science View on PubMed

Abstract

Monotherapy is an ineffective way to treat hepatitis C and it leads to rapid development of resistance. An increasing number of drugs are currently being developed for the treatment of hepatitis C. This allows combination strategies that can overcome the development of resistance and improve sustained virologic response rates. This article focuses on the 2 main strategies in development: quadruple combination therapies, including pegylated-interferon and triple/quadruple pegylated-interferon free combination therapies. If the first combinations are leading to extremely high sustained virologic responses, the second ones offer hope that the era of pegylated-interferon will end soon.

Address: Division of Liver Diseases, Department of Medicine, Mount Sinai School of Medicine, New York, NY 10029, USA. [email protected]

DOI: 10.1016/j.cld.2012.09.001

Link outs

Free resources

Medical:

https://medlineplus.gov/hepatitisc.html

Other Literature Sources:

https://scite.ai/reports/23177285

Subscription / membership required

Full Text Sources:

MeSH Terms: Antiviral Agents, Drug Therapy, Combination, Hepacivirus, Hepatitis C, Humans, Interferons, Peptides, Cyclic, Phosphinic Acids, Polyethylene Glycols, Protease Inhibitors, Quinolines, Ribavirin, Sofosbuvir, Uridine Monophosphate